The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC. The FDA in June announced a new national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are supporting “U.S. national interests,” but previous announcements did not explicitly mention making drugs more affordable as a criterion. But it is unclear how the Trump administration will consider affordability when reviewing a drug, as prices for a product’s launch are usually determined after an approval in the U.S.
The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.